CDH17 and metastatic malignant neoplasm in the lymph nodes: Aside from the associations previously noted, we did not obtain statistically significant results for CDH17 immunohistochemical expression in tumor core/invasive front/tumor emboli/lymph node metastasis and other clinicopathological characteristics, such as gender, N status, LVI, IMVI, EMVI, IPNI, prognostic stage group, and tumor growth pattern.